fbpx

molecules of the month

LYC-55716

oral ROR_ nuclear receptor agonist

450 mg BID, phase I/II, cancer

from change in MoA of ROR_ antagonist + opt.

Journal of Medicinal Chemistry

Lycera

Chemical structure of molecule LYC-55716 Cintirorgon
1 min read

The Lycera ROR gamma agonist, cintirorgon (LYC-55716), is a first-in-class phase 1b clinical candidate for cancer immunotherapy (in combination with pembrolizumab in NSCLC). ROR gamma antagonists have been extensively pursued and studied for autoimmune conditions, but ROR gamma agonists have also been recently pursued for “pro-inflammatory” cancer immunotherapy. An interesting aspect of this story is that the agonists are derived from small changes to antagonists through replacement of an amide by groups without an H-bond donor. The H-bond donor of antagonist amide is hypothesized to be important to disrupting the structure of the nuclear receptor and disfavoring co-activator binding.


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: